Phakic Intraocular Lenses (IOL) Market- Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

The Phakic Intraocular Lenses (IOL) Market is projected to grow from USD 427.9 million in 2024 to an estimated USD 827.9 million by 2032, with a compound annual growth rate (CAGR) of 8.6% from 2024 to 2032.

This growth is primarily driven by the rising incidence of myopia and other refractive errors, coupled with the growing demand for better, long-term vision correction solutions. Phakic IOLs offer several advantages, such as more predictable visual outcomes and a reduced risk of complications compared to traditional refractive surgeries. Additionally, advancements in lens design, improvements in materials, and increasing surgical precision are enhancing the appeal of Phakic IOLs among both ophthalmologists and patients. The shift toward minimally invasive and more effective treatments further supports the rising demand for these devices, particularly among individuals seeking alternatives to glasses or contact lenses.

Market Drivers:

Increasing Prevalence of Refractive Errors:

The rising incidence of refractive errors, particularly high myopia, is a major driver of the growth in the Phakic IOL market. As the global population continues to age, the prevalence of refractive vision disorders is expected to increase, with an increasing number of individuals requiring corrective treatments. For example, studies have shown that the prevalence of myopia among schoolchildren in India ranges from 1.57% at ages 5-9 years to 4.8% at ages 15-18 years. Phakic IOLs offer an effective solution for patients with high degrees of myopia who are not suitable candidates for conventional laser eye surgeries. This growing demand for corrective eye surgeries is fueling market growth as patients seek permanent, reliable, and minimally invasive alternatives to glasses or contact lenses.

Market Challenges:

High Cost of Procedures:

One significant challenge in the Phakic IOL market is the relatively high cost of the procedures. The implantation of Phakic IOLs typically involves expensive surgery, including pre-operative assessments, the cost of the lenses themselves, and post-operative care. This can make the procedure unaffordable for a significant portion of the global population, particularly in emerging markets. The financial burden associated with Phakic IOL implantation may limit its accessibility, slowing down broader market adoption, especially in price-sensitive regions.

Segmentation:

By Product:

Posterior Chamber Phakic IOL

Anterior Chamber Phakic IOL

By Indication:

Hyperopia

Astigmatism

Myopia

By End-User:

Ophthalmology Clinics

Hospitals

Ambulatory Surgical Centers

By Region:

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

Southeast Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Key Players:

STAAR SURGICAL

Johnson & Johnson

Ambu

Verathon Inc.

Duomed

Care Group

Ophtec BV/Abbott

Boston Scientific

Olympus

PENTAX Medical




Show more